Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma

Inclusion Criteria:• Informed consent

* Age \> 18 years
* Performance status 0-1; expected survival ≥ 3 months
* Patient with histologically or cytologically adenocarcinoma developed from cells in the gall bladder, extra- or intrahepatic bile ducts or malignant cells consistent with above mentioned and radiologic findings consistent with cholangiocarcinoma
* Liver metastases not suitable for surgery or other local treatment
* Extrahepatic disease should be excluded by PET-CT-scan.
* Prior treatment with chemotherapy or no progression on first line treatment
* Metastases \< 70 % of the liver
* neutrophile granulocytes ≥ 1.5 x 109/l og thrombocytes ≥ 100 x 109/l
* bilirubin \< 2.0 x UNL (upper normal limit).
* creatinine-clearance ≥ 30 ml/min.
* INR \< 2.
* Intrahepatic treatment can be accomplished
* The patients is approved by a multidisciplinary team

Exclusion Criteria:• Other current or prior malignant disease except adequately treated and cured carcinoma in situ of the cervix or squamous cell carcinoma of the skin.

* Cytotoxic or experimental treatment within a 14 days period before start of trial medication
* The patient is not allowed to participate in other clinical trials.
* Any clinical symptoms suggesting peripheral neuropathy grade 2
* Other severe medical conditions
* Severe cardial disease or AMI \< 1 year
* Presence of diseases preventing oral therapy
* Patients with uncontrolled infection
* Pregnant or lactating women
* Women capable of childbearing not using a sufficient method of birth control
* Patients not able to understand the treatment or to collaborate
* Prior serious or unsuspected reaction after treatment with fluoropyrimidine
* Known prior hypersensitivity reactions to the agents
* Interstitial pneumonitis or pulmonary fibrosis